Mirum Pharmaceuticals: Rare-Disease Platform, Not a One-Drug Story
Mirum (MIRM) has moved from a single-franchise story into a broader rare-liver disease platform. Revenue growth and an expanding pipeline support upside, but integration costs from the $620M Bluejay deal and conservative 2026 guidance keep risk elevated. Trade idea: enter at current levels, protect with a measured stop, and target meaningful multip…